Clinical Trial Update: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in non-small cell lung cancer; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• tivantinib (tivantinib)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Non-small-cell Lung Cancer | Phase 3 | Status: TERMINATED